🇺🇸 Amlodipine/Olmesartan in United States
188 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 188
Most-reported reactions
- Diarrhoea — 30 reports (15.96%)
- Fatigue — 22 reports (11.7%)
- Nausea — 21 reports (11.17%)
- Pain — 20 reports (10.64%)
- Drug Ineffective — 19 reports (10.11%)
- Dizziness — 18 reports (9.57%)
- Death — 16 reports (8.51%)
- Headache — 16 reports (8.51%)
- Anxiety — 13 reports (6.91%)
- Confusional State — 13 reports (6.91%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Amlodipine/Olmesartan approved in United States?
Amlodipine/Olmesartan does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Amlodipine/Olmesartan in United States?
Radboud University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.